P1059 (10051): A Phase I Open-Label Study to Evaluate the Safety & Tolerability of Recombinant Vaccines in HIV-Infected Young Adults with Good Control of HIV-1 Replication and on Stable Highly Active Antiretroviral Therapy
|Study Status||Study Restriction|
What is P1059?
P1059 was Phase I, open-label study among HIV-infected youth receiving treatment in the United States. The study was designed to determine the safety and tolerability of recombinant MVA and Fowlpox HIV-1 vaccines in HIV-1-infected young adults with good control of HIV replication (HIV RNA < 100 copies/mL for 6 months) on stable antiretroviral therapy.
Sites where the study was implemented:
|CRS ID||Site Name||City||Country|
|No sites at this time.|
|No records returned.|